Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 68

1.

Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy.

Koren S, Bentires-Alj M.

Mol Cell. 2015 Nov 19;60(4):537-46. doi: 10.1016/j.molcel.2015.10.031. Review.

PMID:
26590713
2.

The seventh ENBDC workshop on methods in mammary gland development and cancer.

Glukhova MA, Hynes N, Vivanco Md, van Amerongen R, Clarke RB, Bentires-Alj M.

Breast Cancer Res. 2015 Sep 2;17(1):119. doi: 10.1186/s13058-015-0629-5.

3.

PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours.

Koren S, Reavie L, Couto JP, De Silva D, Stadler MB, Roloff T, Britschgi A, Eichlisberger T, Kohler H, Aina O, Cardiff RD, Bentires-Alj M.

Nature. 2015 Sep 3;525(7567):114-8. doi: 10.1038/nature14669. Epub 2015 Aug 12.

PMID:
26266975
4.

Stimulating translational research: several European life science institutions put their heads together.

Bentires-Alj M, Rajan A, van Harten W, van Luenen HG, Kubicek S, Andersen JB, Saarela J, Cook SJ, Van Minnebruggen G, Roman-Roman S, Maurer C, Erler JT, Bertero MG.

Trends Mol Med. 2015 Sep;21(9):525-7. doi: 10.1016/j.molmed.2015.07.002. Epub 2015 Aug 5.

PMID:
26254816
5.

CUB-domain-containing protein 1 overexpression in solid cancers promotes cancer cell growth by activating Src family kinases.

Leroy C, Shen Q, Strande V, Meyer R, McLaughlin ME, Lezan E, Bentires-Alj M, Voshol H, Bonenfant D, Alex Gaither L.

Oncogene. 2015 Oct 29;34(44):5593-8. doi: 10.1038/onc.2015.19. Epub 2015 Mar 2.

PMID:
25728678
6.

Breast cancer prevention: lessons to be learned from mechanisms of early pregnancy-mediated breast cancer protection.

Meier-Abt F, Bentires-Alj M, Rochlitz C.

Cancer Res. 2015 Mar 1;75(5):803-7. doi: 10.1158/0008-5472.CAN-14-2717. Epub 2015 Feb 6.

PMID:
25660950
7.

Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis.

Bonapace L, Coissieux MM, Wyckoff J, Mertz KD, Varga Z, Junt T, Bentires-Alj M.

Nature. 2014 Nov 6;515(7525):130-3. doi: 10.1038/nature13862. Epub 2014 Oct 22.

PMID:
25337873
8.

Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.

Ramos P, Bentires-Alj M.

Oncogene. 2015 Jul;34(28):3617-26. doi: 10.1038/onc.2014.314. Epub 2014 Sep 29. Review.

PMID:
25263438
9.

Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine.

Leroy C, Amante RJ, Bentires-Alj M.

Biochem Soc Trans. 2014 Aug;42(4):733-41. doi: 10.1042/BST20140034. Review.

PMID:
25109950
10.
11.

Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases.

Sausgruber N, Coissieux MM, Britschgi A, Wyckoff J, Aceto N, Leroy C, Stadler MB, Voshol H, Bonenfant D, Bentires-Alj M.

Oncogene. 2015 Apr 23;34(17):2272-8. doi: 10.1038/onc.2014.170. Epub 2014 Jun 16.

PMID:
24931162
12.

Memo is a copper-dependent redox protein with an essential role in migration and metastasis.

MacDonald G, Nalvarte I, Smirnova T, Vecchi M, Aceto N, Dolemeyer A, Frei A, Lienhard S, Wyckoff J, Hess D, Seebacher J, Keusch JJ, Gut H, Salaun D, Mazzarol G, Disalvatore D, Bentires-Alj M, Di Fiore PP, Badache A, Hynes NE.

Sci Signal. 2014 Jun 10;7(329):ra56. doi: 10.1126/scisignal.2004870.

PMID:
24917593
13.

Mesenchymal precursor cells maintain the differentiation and proliferation potentials of breast epithelial cells.

Duss S, Brinkhaus H, Britschgi A, Cabuy E, Frey DM, Schaefer DJ, Bentires-Alj M.

Breast Cancer Res. 2014 Jun 10;16(3):R60. doi: 10.1186/bcr3673.

14.

MDM2 restrains estrogen-mediated AKT activation by promoting TBK1-dependent HPIP degradation.

Shostak K, Patrascu F, Göktuna SI, Close P, Borgs L, Nguyen L, Olivier F, Rammal A, Brinkhaus H, Bentires-Alj M, Marine JC, Chariot A.

Cell Death Differ. 2014 May;21(5):811-24. doi: 10.1038/cdd.2014.2. Epub 2014 Jan 31.

15.

VEGF-mediated angiogenesis links EMT-induced cancer stemness to tumor initiation.

Fantozzi A, Gruber DC, Pisarsky L, Heck C, Kunita A, Yilmaz M, Meyer-Schaller N, Cornille K, Hopfer U, Bentires-Alj M, Christofori G.

Cancer Res. 2014 Mar 1;74(5):1566-75. doi: 10.1158/0008-5472.CAN-13-1641. Epub 2014 Jan 10.

16.

How pregnancy at early age protects against breast cancer.

Meier-Abt F, Bentires-Alj M.

Trends Mol Med. 2014 Mar;20(3):143-53. doi: 10.1016/j.molmed.2013.11.002. Epub 2013 Dec 16. Review.

PMID:
24355762
17.

Targeting PI3K, HER2 and the IL-8/JAK2 axis in metastatic breast cancer: Which combination makes the whole greater than the sum of its parts?

Britschgi A, Radimerski T, Bentires-Alj M.

Drug Resist Updat. 2013 Jul-Nov;16(3-5):68-72. doi: 10.1016/j.drup.2013.10.001. Epub 2013 Oct 10. Review.

PMID:
24169539
19.

Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R.

Meyer DS, Koren S, Leroy C, Brinkhaus H, Müller U, Klebba I, Müller M, Cardiff RD, Bentires-Alj M.

Oncogenesis. 2013 Sep 30;2:e74. doi: 10.1038/oncsis.2013.38.

20.

Mammary tumor formation and metastasis evoked by a HER2 splice variant.

Alajati A, Sausgruber N, Aceto N, Duss S, Sarret S, Voshol H, Bonenfant D, Bentires-Alj M.

Cancer Res. 2013 Sep 1;73(17):5320-7. doi: 10.1158/0008-5472.CAN-12-3186. Epub 2013 Jul 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk